Bayer Aktiengesellschaft (BAYRY)
| Market Cap | 20.11B |
| Revenue (ttm) | 52.13B |
| Net Income (ttm) | -981.49M |
| Shares Out | n/a |
| EPS (ttm) | -1.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.02 (0.40%) |
| Ex-Dividend Date | Apr 29, 2024 |
| Volume | 21,532 |
| Open | 5.10 |
| Previous Close | 5.09 |
| Day's Range | 5.10 - 5.16 |
| 52-Week Range | 5.05 - 9.79 |
| Beta | 0.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2024 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare produc... [Read more]
News
Bayer Announces ‘Project Enhanced S3' to Enable Companies to Realize Additional Sustainability Value from Carbon Removal Projects
ST. LOUIS--(BUSINESS WIRE)--Bayer announced today an expanded approach to its programs that sequester carbon and reduce emissions for companies along the food value chain through regenerative agricult...
Cytokinetics and Bayer partner to develop for aficamten in Japan
Bayer (BAYRY) and Cytokinetics (CYTK) Collaborate on Japanese HCM Therapy
Bayer (BAYRY) and Cytokinetics (CYTK) Collaborate on Japanese HCM Therapy
Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
Bayer acquires rights to Cytokinetics' heart drug in Japan
Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular bu...
Bayer Faces Investor Pressure to Accelerate Turnaround Amid Record Lows
Bayer is under growing pressure from investors to expedite its turnaround strategy as CEO Bill Anderson grapples with slumping earnings and a 20-year low in the company’s share price following a stark...
Bayer’s Worst Week in a Year Puts Scale of CEO Task Into Context
As Bayer AG shares head for their worst week in almost a year, the days of 2015 when the German company was valued at more than €120 billion ($127 billion) are an even more distant memory.
Bayer shareholders call on CEO to stem the tide of bad news
Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development, to restore confidence and revive the company's share price that hit 2...
Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF ≥40% at AHA 2024
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDIA® (finerenone) i...
Bayer AG (BAYRY) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges
Bayer AG (BAYRY) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges
Q3 2024 Bayer AG Earnings Call Transcript
Q3 2024 Bayer AG Earnings Call Transcript
Bayer AG (BAYZF) Q3 2024 Earnings Call Transcript
Bayer’s turnaround just got even tougher
Deteriorating market conditions mean chief executive Bill Anderson will have to dig even deeper
Bayer shares fall as pharma giant’s results fail to cheer investors
Bayer’s share price fell on Tuesday, following the company releasing lacklustre third quarter earnings with a warning that the current challenges may also impact next year’s results as well.
Bayer Aktiengesellschaft 2024 Q3 - Results - Earnings Call Presentation
Bayer Stock: Assessing Upside Potential After Its Q3 Earnings
Bayer reported Q3 earnings results recently. Despite litigation risks and poor M&As, check out why I am maintaining my Buy rating on Bayer stock.
Bayer Stock Slumps on Outlook Cut
Bayer shares are falling 11% in German trading after the pharmaceuticals and crop science conglomerate reduced its full-year earnings target and warned of likely lower profit next year amid a tough ag...
Bayer drops after guidance cut
Chemical giant Bayer reports heavy drop in profit amid ongoing Roundup cancer lawsuit
The group reported a net loss of 4.18 billion euros in the third quarter, with revenues in its agricultural unit down 3.6 percent.
Bayer cuts profits forecast and reports €4bn loss
German conglomerate’s chief admits numbers are not ‘pretty’ amid forecast of ‘muted outlook’ for next year
Bayer shares slump after warning on crop sciences unit
Bayer Cuts Earnings Target, Posts Net Loss on Agriculture Weakness
Bayer AG Non-GAAP EPS of €0.24, revenue of €9.97B; reaffirms FY24 core EPS outlook
Bayer Lowers Earnings Guidance on Weak Crop Unit Performance
Bayer AG cut its profit outlook for the year on stubbornly low prices for agriculture products, including the controversial weedkiller Roundup.
Bayer cuts FY operating earnings outlook on weak agriculture markets
Bayer on Tuesday lowered its full-year operating earnings guidance, citing weaker agricultural markets in Latin America.